Halozyme Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$HALO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | ||||||||
(Exact name of registrant as specified in its charter)
________________________
Commission File Number 001-32335
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||
| (Zip Code) | ||||||||
| (Address of principal executive offices) | ||||||||
(858 ) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 5, 2026, Halozyme Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. Of the 118,474,300 shares of the Company's common stock outstanding as of the record date, 104,138,244 shares were represented at the annual meeting.
The stockholders considered three proposals at the meeting, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 23, 2026. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below..
Proposal 1: Election of two Class I directors to hold office for a three-year term expiring at the 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified:
| Names | Votes For | Votes Against | Abstain | Broker Non-Votes | ||||||||||||||||||||||
Bernadette Connaughton | 89,053,734 | 5,068,160 | 127,131 | 9,889,219 | ||||||||||||||||||||||
Matthew L. Posard | 82,739,433 | 10,236,878 | 1,272,714 | 9,889,219 | ||||||||||||||||||||||
Each of the foregoing candidates was elected and each received affirmative votes from more than a majority of the outstanding shares.
Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows:
| Votes For | Votes Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 84,682,518 | 9,311,426 | 255,081 | 9,889,219 | |||||||||||||||||
The foregoing proposal was approved.
Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows:
| Votes For | Votes Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 103,197,579 | 849,433 | 91,232 | --- | |||||||||||||||||
The foregoing proposal was approved.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HALOZYME THERAPEUTICS, INC. (Registrant) | |||||||||||||||||
| Dated: | May 7, 2026 | By: | /s/ Mark Snyder | ||||||||||||||
| Mark Snyder | |||||||||||||||||
| Senior Vice President, General Counsel and Corporate Secretary | |||||||||||||||||